AstraZeneca PLC(NASDAQ:AZN) 
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhe...
Website: http://www.astrazeneca.com
Founded: 1999
Full Time Employees: 70,600
CEO: Pascal Soriot
Sector: Healthcare
Industry: Drug Manufacturers-General
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2020-04-29 | 2020-02-14 | 2019-10-24 | 2019-06-30 | 2019-04-26 | 2019-02-14 | 2018-07-26 | 2018-02-02 | 2017-11-09 | 2017-07-27 | 2017-04-27 | 2017-02-02 | 2016-12-31 | 2016-11-10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
total revenue | 6,354,000,000 | 24,384,000,000 | 17,720,000,000 | 11,314,000,000 | 5,491,000,000 | 22,090,000,000 | 10,333,000,000 | 22,465,000,000 | 16,688,000,000 | 10,456,000,000 | 5,405,000,000 | 23,002,000,000 | -17,416,999,756 | 17,417,000,000 |
yoy | 15.72% | 10.38% | 71.49% | -49.64% | -67.10% | 111.27% | 91.17% | -2.33% | -195.81% | -39.97% | ||||
qoq | -73.94% | 37.61% | 56.62% | 106.05% | -75.14% | 113.78% | -54.00% | 34.62% | 59.60% | 93.45% | -76.50% | -232.07% | -200.00% | |
product sales | 6,311,000,000 | 23,565,000,000 | 17,315,000,000 | 11,183,000,000 | 5,465,000,000 | 21,049,000,000 | 10,015,000,000 | 20,152,000,000 | 14,665,000,000 | 9,783,000,000 | 4,843,000,000 | 21,319,000,000 | -16,059,000,387 | 16,059,000,000 |
collaboration revenue | 43,000,000 | 819,000,000 | 405,000,000 | 131,000,000 | 26,000,000 | |||||||||
cost of sales | -1,420,000,000 | -4,921,000,000 | -3,543,000,000 | -1,129,000,000 | -4,936,000,000 | -4,318,000,000 | -3,093,000,000 | -1,844,000,000 | -894,000,000 | -4,126,000,000 | 2,966,000,700 | -2,966,000,000 | ||
gross profit | 4,934,000,000 | 19,463,000,000 | 14,177,000,000 | 9,122,000,000 | 4,362,000,000 | 17,154,000,000 | 8,187,000,000 | 18,147,000,000 | 13,595,000,000 | 8,612,000,000 | 4,511,000,000 | 18,876,000,000 | -14,450,999,056 | 14,451,000,000 |
yoy | 13.11% | 13.46% | 73.16% | -49.73% | -67.91% | 99.19% | 81.49% | -3.86% | -194.08% | -40.41% | ||||
qoq | -74.65% | 37.29% | 55.42% | 109.12% | -74.57% | 109.53% | -54.89% | 33.48% | 57.86% | 90.91% | -76.10% | -230.62% | -200.00% | |
gross margin % | 77.65% | 79.82% | 80.01% | 80.63% | 79.44% | 77.66% | 79.23% | 80.78% | 81.47% | 82.36% | 83.46% | 82.06% | 82.97% | 82.97% |
distribution costs | -87,000,000 | -339,000,000 | -247,000,000 | -78,000,000 | -331,000,000 | -310,000,000 | -225,000,000 | -149,000,000 | -77,000,000 | -326,000,000 | 242,999,944 | -243,000,000 | ||
research and development expense | -1,388,000,000 | -6,059,000,000 | -3,968,000,000 | -1,266,000,000 | -5,932,000,000 | -5,757,000,000 | -4,206,000,000 | -2,802,000,000 | -1,453,000,000 | -5,890,000,000 | 4,346,999,150 | -4,347,000,000 | ||
selling, general and administrative costs | -2,719,000,000 | -11,682,000,000 | -8,656,000,000 | -2,514,000,000 | -10,031,000,000 | -10,233,000,000 | -7,155,000,000 | -4,658,000,000 | -2,300,000,000 | -9,413,000,000 | 8,027,001,008 | -8,027,000,000 | ||
other operating income and expense | 480,000,000 | 1,541,000,000 | 1,041,000,000 | 706,000,000 | 593,000,000 | 2,527,000,000 | 1,830,000,000 | 982,000,000 | 839,000,000 | 236,000,000 | 1,655,000,000 | -534,998,811 | 535,000,000 | |
operating profit | 1,220,000,000 | 2,924,000,000 | 2,347,000,000 | 1,590,000,000 | 1,097,000,000 | 3,387,000,000 | 1,459,000,000 | 3,677,000,000 | 2,991,000,000 | 1,842,000,000 | 917,000,000 | 4,902,000,000 | -2,368,997,765 | 2,369,000,000 |
yoy | 11.21% | -13.67% | 60.86% | -56.76% | -63.32% | 83.88% | 59.11% | -24.99% | -226.26% | -22.25% | ||||
qoq | -58.28% | 24.58% | 47.61% | 44.94% | -67.61% | 132.15% | -60.32% | 22.94% | 62.38% | 100.87% | -81.29% | -306.92% | -200.00% | |
operating margin % | 19.20% | 11.99% | 13.24% | 14.05% | 19.98% | 15.33% | 14.12% | 16.37% | 17.92% | 17.62% | 16.97% | 21.31% | 13.60% | 13.60% |
finance income | 51,000,000 | 172,000,000 | 133,000,000 | 96,000,000 | 55,000,000 | 138,000,000 | 78,000,000 | 113,000,000 | 71,000,000 | 39,000,000 | 18,000,000 | 67,000,000 | 11,000,000 | 44,000,000 |
finance expense | -332,000,000 | -1,432,000,000 | -1,081,000,000 | -367,000,000 | -1,419,000,000 | -1,508,000,000 | -1,199,000,000 | -781,000,000 | -340,000,000 | -1,384,000,000 | -255,500,000 | -1,022,000,000 | ||
share of after-tax losses in associates and joint ventures | -116,000,000 | -91,000,000 | -27,000,000 | |||||||||||
profit before tax | 935,000,000 | 1,548,000,000 | 1,308,000,000 | 899,000,000 | 758,000,000 | 1,993,000,000 | 786,000,000 | 2,227,000,000 | 1,820,000,000 | 1,074,000,000 | 582,000,000 | 3,552,000,000 | 342,250,000 | 1,369,000,000 |
taxation | -185,000,000 | -321,000,000 | -358,000,000 | -195,000,000 | 57,000,000 | 641,000,000 | -213,000,000 | -116,000,000 | -70,000,000 | -146,000,000 | 55,000,000 | 220,000,000 | ||
profit for the period | 750,000,000 | 1,227,000,000 | 950,000,000 | 670,000,000 | 563,000,000 | 2,050,000,000 | 635,000,000 | 2,868,000,000 | 1,607,000,000 | 958,000,000 | 512,000,000 | 3,406,000,000 | 397,250,000 | 1,589,000,000 |
other comprehensive income | ||||||||||||||
items that will not be reclassified to profit or loss | ||||||||||||||
remeasurement of the defined benefit pension liability | 440,000,000 | -364,000,000 | -151,000,000 | 10,000,000 | -46,000,000 | 187,000,000 | -242,000,000 | -146,000,000 | -271,000,000 | 1,000,000 | -575,000,000 | -281,750,000 | -1,127,000,000 | |
net gains on equity investments measured at fair value through other comprehensive income | 171,000,000 | 120,000,000 | ||||||||||||
fair value movements related to own credit risk on bonds designated as fair value through profit or loss | 21,000,000 | 8,000,000 | ||||||||||||
tax on items that will not be reclassified to profit or loss | -66,000,000 | 21,000,000 | 21,000,000 | 17,000,000 | -43,000,000 | 56,000,000 | 16,000,000 | 23,000,000 | 71,000,000 | 136,000,000 | 64,000,000 | 256,000,000 | ||
items that may be reclassified subsequently to profit or loss | ||||||||||||||
foreign exchange arising on consolidation | -608,000,000 | 40,000,000 | -385,000,000 | 53,000,000 | -450,000,000 | 536,000,000 | 531,000,000 | 377,000,000 | 154,000,000 | -1,050,000,000 | -172,500,000 | -690,000,000 | ||
foreign exchange arising on designating borrowings in net investment hedges | -380,000,000 | -252,000,000 | -491,000,000 | -180,000,000 | -520,000,000 | 505,000,000 | 622,000,000 | 383,000,000 | 100,000,000 | -591,000,000 | -48,500,000 | -194,000,000 | ||
fair value movements on cash flow hedges | -187,000,000 | -54,000,000 | -37,000,000 | 311,000,000 | 226,000,000 | 127,000,000 | 7,000,000 | -115,000,000 | -6,500,000 | -26,000,000 | ||||
fair value movements on cash flow hedges transferred to profit or loss | 45,000,000 | 47,000,000 | 111,000,000 | 69,000,000 | -315,000,000 | -281,000,000 | -200,000,000 | -39,000,000 | 195,000,000 | 10,250,000 | 41,000,000 | |||
fair value movements on derivatives designated in net investment hedges | 60,000,000 | 3,000,000 | -48,000,000 | -39,000,000 | -35,000,000 | -30,000,000 | -24,000,000 | -96,000,000 | ||||||
costs of hedging | -47,000,000 | -35,000,000 | 3,000,000 | |||||||||||
tax on items that may be reclassified subsequently to profit or loss | 73,000,000 | 38,000,000 | 62,000,000 | 20,000,000 | 23,000,000 | 51,000,000 | 55,000,000 | -33,000,000 | -125,000,000 | -70,000,000 | 24,000,000 | 86,000,000 | 15,750,000 | 63,000,000 |
other comprehensive loss for the period, net of tax | -436,000,000 | -611,000,000 | -1,128,000,000 | |||||||||||
total comprehensive income for the period | 314,000,000 | 616,000,000 | 97,000,000 | 535,000,000 | 991,000,000 | 215,000,000 | 3,507,000,000 | 578,000,000 | 1,628,000,000 | -14,250,000 | -57,000,000 | |||
profit attributable to: | ||||||||||||||
owners of the parent | 780,000,000 | 1,335,000,000 | 1,022,000,000 | 723,000,000 | 593,000,000 | 2,155,000,000 | 690,000,000 | 3,001,000,000 | 1,700,000,000 | 1,014,000,000 | 537,000,000 | 3,499,000,000 | 414,250,000 | 1,657,000,000 |
non-controlling interests | -30,000,000 | -108,000,000 | -72,000,000 | -30,000,000 | -105,000,000 | -133,000,000 | -93,000,000 | -56,000,000 | -25,000,000 | -93,000,000 | -17,000,000 | -68,000,000 | ||
total comprehensive income attributable to: | ||||||||||||||
basic earnings per 0.25 ordinary share | 590,000 | 1,030,000 | 790,000 | 560,000 | 470,000 | 1,700,000 | 540,000 | 2,370,000 | 1,340,000 | 800,000 | 420,000 | 2,770,000 | 327,500 | 1,310,000 |
diluted earnings per 0.25 ordinary share | 590,000 | 1,030,000 | 790,000 | 560,000 | 470,000 | 1,700,000 | 540,000 | 2,370,000 | 1,340,000 | 800,000 | 420,000 | 2,760,000 | 327,500 | 1,310,000 |
weighted-average number of ordinary shares in issue | 1,312,000,000 | 1,301,000,000 | 1,297,000,000 | 1,289,000,000 | 1,267,000,000 | 1,267,000,000 | 1,267,000,000 | 1,266,000,000 | 1,266,000,000 | 1,266,000,000 | 1,265,000,000 | 1,265,000,000 | 1,265,000,000 | |
diluted weighted-average number of ordinary shares in issue | 1,313,000,000 | 1,301,000,000 | 1,297,000,000 | 1,290,000,000 | 1,268,000,000 | 1,267,000,000 | 1,267,000,000 | 1,267,000,000 | 1,266,000,000 | 1,266,000,000 | 1,266,000,000 | 1,266,000,000 | 1,266,000,000 | |
for the year ended 31 december | ||||||||||||||
net incomees on equity investments measured at fair value through other comprehensive income | -28,000,000 | -171,000,000 | ||||||||||||
fair-value movements related to own credit risk on bonds designated as fair-value through profit or loss | ||||||||||||||
fair-value movements on cash flow hedges | -101,000,000 | -156,000,000 | ||||||||||||
fair-value movements on cash flow hedges transferred to profit or loss | 52,000,000 | 109,000,000 | 14,000,000 | |||||||||||
fair-value movements on derivatives designated in net investment hedges | 35,000,000 | 35,000,000 | ||||||||||||
amortisation of loss on cash flow hedge | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 250,000 | 1,000,000 | |||||||
for the nine months ended 30 september | ||||||||||||||
net (losses)/gains on equity investments measured at fair value through other comprehensive income | -136,000,000 | |||||||||||||
total comprehensive (loss)/income for the period | -178,000,000 | |||||||||||||
for the half year ended 30 june | ||||||||||||||
other comprehensive income for the period, net of tax | -28,000,000 | 66,000,000 | -1,778,000,000 | -411,500,000 | -1,646,000,000 | |||||||||
externalisation revenue | 1,041,000,000 | 318,000,000 | 2,313,000,000 | 2,023,000,000 | 673,000,000 | 562,000,000 | 1,683,000,000 | -1,357,999,369 | 1,358,000,000 | |||||
share of after tax losses in associates and joint ventures | -113,000,000 | -55,000,000 | -43,000,000 | -26,000,000 | -13,000,000 | -33,000,000 | -5,500,000 | -22,000,000 | ||||||
fair value movements on derivatives designated in net investment hedges costs of hedging | -54,000,000 | |||||||||||||
net available for sale losses taken to equity | -94,000,000 | -150,000,000 | ||||||||||||
other comprehensive (loss)/income for the period, net of tax | -1,059,000,000 | |||||||||||||
other operating income & expense | 1,086,000,000 | |||||||||||||
fair value movements on equity investments | 156,000,000 | |||||||||||||
other comprehensive income/ | ||||||||||||||
net available for sale (losses)/gains taken to equity | -83,000,000 | -36,000,000 | ||||||||||||
other comprehensive income/(loss) for the period, net of tax | 639,000,000 | 776,000,000 | 289,000,000 | |||||||||||
total comprehensive income/(loss) for the period | 2,383,000,000 | 1,247,000,000 | ||||||||||||
total comprehensive income/(loss) attributable to: | ||||||||||||||
net available for sale gains/(losses) taken to equity | 139,000,000 | 31,500,000 | 126,000,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-11-06 | 2025-06-30 | 2025-02-06 | 2024-06-30 | 2024-04-25 | 2024-02-08 | 2023-11-02 | 2021-02-11 | 2020-04-29 | 2020-02-14 | 2019-10-24 | 2019-06-30 | 2019-04-26 | 2019-02-14 | 2018-07-26 | 2018-05-18 | 2018-02-14 | 2018-02-02 | 2017-11-09 | 2017-07-27 | 2017-04-27 | 2017-02-02 | 2016-11-10 | 2016-02-02 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||
non-current assets | ||||||||||||||||||||||||
property, plant and equipment | 12,083 | 11,637 | 10,252 | 9,630 | 9,411 | 9,402 | 8,723 | 8,251 | 7,347,000,000 | 7,688 | 7,317,000,000 | 7,442 | 7,446,000,000 | 7,421 | 7,514 | 7,721 | 7,421,000,000 | 7,615 | 7,329,000,000 | 7,079 | 6,954 | 6,848 | 6,690 | 6,848,000,000 |
right-of-use assets | 1,700 | 1,592 | 1,395 | 1,203 | 1,205 | 1,100 | 977 | 666 | 644,000,000 | 647 | 690,000,000 | 702 | 707,000,000 | |||||||||||
goodwill | 21,219 | 21,222 | 21,025 | 21,060 | 19,978 | 20,048 | 19,939 | 11,845 | 11,569,000,000 | 11,668 | 11,595,000,000 | 11,668 | 11,674,000,000 | 11,707 | 11,717 | 11,834 | 11,707,000,000 | 11,825 | 11,841,000,000 | 11,774 | 11,688 | 11,658 | 11,806 | 11,658,000,000 |
intangible assets | 38,191 | 37,925 | 37,177 | 39,426 | 38,834 | 38,089 | 37,687 | 20,947 | 19,718,000,000 | 20,833 | 21,454,000,000 | 22,257 | 22,852,000,000 | 21,959 | 24,887 | 25,850 | 21,959,000,000 | 26,188 | 27,124,000,000 | 27,465 | 27,386 | 27,586 | 28,507 | 27,586,000,000 |
investments in associates and joint ventures | 296 | 276 | 268 | 264 | 130 | 147 | 62 | 39 | 44,000,000 | 58 | 43,000,000 | 73 | 76,000,000 | 89 | 157 | 187 | 89,000,000 | 103 | 78,000,000 | 86 | 88 | 99 | 95 | 99,000,000 |
other investments | 1,990 | 1,863 | 1,632 | 1,607 | 1,565 | 1,530 | 1,228 | 1,108 | 1,476,000,000 | 1,401 | 1,293,000,000 | 1,362 | 1,530,000,000 | 833 | 1,089 | 987 | 833,000,000 | 933 | 1,004,000,000 | 989 | 739 | 727 | 715 | 727,000,000 |
derivative financial instruments | 502 | 509 | 182 | 217 | 213 | 228 | 151 | 171 | 104,000,000 | 61 | 56,000,000 | 124 | 94,000,000 | 157 | 459 | 594 | 157,000,000 | 504 | 440,000,000 | 336 | 310 | 343 | 278 | 343,000,000 |
other receivables | 1,159 | 1,066 | 930 | 806 | 745 | 803 | 761 | 720 | 527,000,000 | 740 | 384,000,000 | 454 | 496,000,000 | 515 | 738 | 525 | 515,000,000 | 847 | 953,000,000 | 967 | 891 | 901 | 681 | 901,000,000 |
income tax receivable | 1,247 | 1,137 | 1,859 | 1,575 | 1,153 | 1,426 | 697 | 364 | 262,000,000 | 285 | 228,000,000 | 246 | 118,000,000 | 207 | 264 | 563 | 207,000,000 | 721,000,000 | 786 | 627 | 426 | 640 | 426,000,000 | |
deferred tax assets | 6,129 | 6,256 | 5,347 | 4,734 | 4,618 | 4,718 | 4,057 | 3,438 | 2,960,000,000 | 2,718 | 2,554,000,000 | 2,588 | 2,531,000,000 | 2,379 | 2,334 | 2,401 | 2,379,000,000 | 2,189 | 2,184,000,000 | 2,125 | 1,266 | 1,102 | 1,584 | 1,102,000,000 |
current assets | ||||||||||||||||||||||||
inventories | 6,593 | 6,467 | 5,288 | 5,667 | 5,337 | 5,424 | 5,292 | 4,024 | 3,123,000,000 | 3,193 | 3,129,000,000 | 3,197 | 3,050,000,000 | 2,890 | 3,118 | 3,283 | 2,890,000,000 | 3,035 | 3,162,000,000 | 2,901 | 2,652 | 2,334 | 2,420 | 2,334,000,000 |
trade and other receivables | 14,338 | 14,168 | 12,972 | 11,047 | 11,072 | 12,126 | 11,300 | 7,022 | 5,080,000,000 | 5,761 | 5,279,000,000 | 5,319 | 5,289,000,000 | 5,574 | 5,257 | 5,444 | 5,574,000,000 | 5,009 | 4,540,000,000 | 4,348 | 4,686 | 4,573 | 5,449 | 4,573,000,000 |
cash and cash equivalents | 8,143 | 7,058 | 5,488 | 6,916 | 7,841 | 5,840 | 4,871 | 7,832 | 3,413,000,000 | 5,369 | 3,967,000,000 | 5,428 | 4,136,000,000 | 4,831 | 2,978 | 3,005 | 4,831,000,000 | 3,324 | 4,036,000,000 | 5,239 | 3,129 | 5,018 | 3,090 | 5,018,000,000 |
total assets | 114,456 | 112,422 | 104,035 | 104,340 | 102,293 | 101,119 | 96,086 | 66,729 | 57,211,000,000 | 61,377 | 58,906,000,000 | 61,889 | 61,055,000,000 | 60,651 | 61,344 | 63,281 | 60,651,000,000 | 63,354 | 64,587,000,000 | 65,119 | 60,959 | 62,526 | 63,222 | 62,526,000,000 |
liabilities | ||||||||||||||||||||||||
current liabilities | ||||||||||||||||||||||||
interest-bearing loans and borrowings | -6,174 | -6,492 | -2,337 | -5,067 | -6,050 | -5,129 | -5,372 | -2,194 | -2,289,000,000 | -1,822 | -228,000,000 | -3,544,000,000 | -1,754 | -4,170 | -1,754,000,000 | -2,247 | -941,000,000 | -2,933 | -2,839 | -2,307 | -2,939 | -2,307,000,000 | ||
lease liabilities | -379 | -361 | -339 | -292 | -281 | -271 | -235 | -192 | -181,000,000 | -188 | -349,000,000 | -175,000,000 | ||||||||||||
trade and other payables | -25,028 | -23,986 | -22,465 | -20,463 | -19,699 | -22,374 | -20,542 | -15,785 | -12,633,000,000 | -13,987 | -12,538,000,000 | -13,102,000,000 | -12,841 | -11,481 | -12,841,000,000 | -11,641 | -10,832,000,000 | -10,072 | -9,899 | -10,486 | -9,961 | -10,486,000,000 | ||
provisions | -1,176 | -1,168 | -1,269 | -1,168 | -1,148 | -1,028 | -1,193 | -976 | -649,000,000 | -723 | -401,000,000 | -397,000,000 | -506 | -1,011 | -506,000,000 | -1,121 | -1,167,000,000 | -1,070 | -1,044 | -1,065 | -936 | -1,065,000,000 | ||
income tax payable | -1,268 | -1,429 | -1,406 | -1,525 | -1,631 | -1,584 | -1,163 | -1,127 | -1,260,000,000 | -1,361 | -1,234,000,000 | -1,010,000,000 | -1,164 | -1,462 | -1,164,000,000 | -1,513,000,000 | -1,576 | -1,646 | -1,380 | -1,534 | -1,380,000,000 | |||
non-current liabilities | ||||||||||||||||||||||||
deferred tax liabilities | -3,604 | -3,615 | -3,305 | -3,333 | -2,621 | -2,844 | -2,752 | -2,918 | -2,501,000,000 | -2,490 | -2,595,000,000 | -3,267,000,000 | -3,286 | -3,987 | -3,286,000,000 | -3,995 | -5,079,000,000 | -4,944 | -4,036 | -3,956 | -4,051 | -3,956,000,000 | ||
retirement benefit obligations | -1,271 | -1,418 | -1,330 | -1,326 | -1,280 | -1,520 | -1,048 | -3,202 | -2,129,000,000 | -2,807 | -2,392,000,000 | -2,385,000,000 | -2,511 | -2,516 | -2,511,000,000 | -2,583 | -2,490,000,000 | -2,534 | -2,171 | -2,186 | -2,870 | -2,186,000,000 | ||
other payables | -2,013 | -1,600 | -1,770 | -2,208 | -2,596 | -2,660 | -2,244 | -6,084 | -6,221,000,000 | -6,291 | -6,848,000,000 | -6,875,000,000 | -6,770 | -7,963 | -6,770,000,000 | -7,840 | -9,807,000,000 | -9,371 | -9,496 | -9,488 | -10,842 | -9,488,000,000 | ||
total liabilities | -68,485 | -67,612 | -63,164 | -64,742 | -64,792 | -61,953 | -58,865 | -51,091 | -44,995,000,000 | -46,781 | -45,237,000,000 | -49,026,000,000 | -46,607 | -48,708 | -46,607,000,000 | -46,712 | -49,140,000,000 | -49,707 | -46,180 | -45,857 | -48,310 | -45,857,000,000 | ||
net assets | 45,971 | 44,810 | 40,871 | 39,598 | 37,501 | 39,166 | 37,221 | 15,638 | 12,216,000,000 | 14,596 | 13,669,000,000 | 15,071 | 12,029,000,000 | 14,044 | 14,272 | 14,573 | 14,044,000,000 | 16,642 | 15,447,000,000 | 15,412 | 14,779 | 16,669 | 14,912 | 16,669,000,000 |
equity | ||||||||||||||||||||||||
share capital | 388 | 388 | 388 | 388 | 388 | 388 | 387 | 328 | 328,000,000 | 328 | 328,000,000 | 328 | 317,000,000 | 317 | 317 | 317 | 317,000,000 | 317 | 316,000,000 | 316 | 316 | 316 | 316 | 316,000,000 |
share premium account | 35,243 | 35,238 | 35,226 | 35,199 | 35,194 | 35,188 | 35,166 | 7,971 | 7,946,000,000 | 7,941 | 7,919,000,000 | 7,911 | 4,438,000,000 | 4,427 | 4,409 | 4,407 | 4,427,000,000 | 4,393 | 4,381,000,000 | 4,374 | 4,368 | 4,351 | 4,344 | 4,351,000,000 |
other reserves | 2,044 | 2,070 | 2,012 | 2,078 | 2,075 | 2,065 | 2,078 | 2,024 | 2,056,000,000 | 2,046 | 2,052,000,000 | 2,044 | 2,046,000,000 | 2,041 | 2,040 | 2,027 | 2,041,000,000 | 2,029 | 2,027,000,000 | 2,033 | 2,042 | 2,047 | 2,031 | 2,047,000,000 |
retained earnings | 8,213 | 7,023 | 3,160 | 1,847 | -212 | 1,502 | -434 | 5,299 | 448,000,000 | 2,812 | 1,865,000,000 | 3,265 | 3,682,000,000 | 5,683 | 5,879 | 6,164 | 5,683,000,000 | 8,221 | 7,001,000,000 | 6,930 | 6,263 | 8,140 | 6,381 | 8,140,000,000 |
capital and reserves attributable to equity holders of the parent | 45,888 | 44,719 | ||||||||||||||||||||||
non-controlling interests | 83 | 91 | 85 | 86 | 56 | 23 | 24 | 16 | 1,438,000,000 | 1,469 | 1,505,000,000 | 1,523 | 1,546,000,000 | 1,576 | 1,627 | 1,658 | 1,576,000,000 | 1,682 | 1,722,000,000 | 1,759 | 1,790 | 1,815 | 1,840 | 1,815,000,000 |
total equity | 45,971 | 44,810 | 40,871 | 39,598 | 37,501 | 39,166 | 37,221 | 15,638 | 12,216,000,000 | 14,596 | 13,669,000,000 | 15,071 | 12,029,000,000 | 14,044 | 14,272 | 14,573 | 14,044,000,000 | 16,642 | 15,447,000,000 | 15,412 | 14,779 | 16,669 | 14,912 | 16,669,000,000 |
| 83,483 | 78,947 | ||||||||||||||||||||||
assets non-current assets | ||||||||||||||||||||||||
liabilities current liabilities | ||||||||||||||||||||||||
assets held for sale | 131,000,000 | 70 | 982 | 982,000,000 | 332 | |||||||||||||||||||
non-current assets - sum | 46,670 | |||||||||||||||||||||||
current assets - sum | 15,219 | |||||||||||||||||||||||
capital and reserves attributable to equity holders of the parent - sum | 13,548 | |||||||||||||||||||||||
capital and reserves attributable to equity holders of the company | ||||||||||||||||||||||||
income tax receivables | 524 | |||||||||||||||||||||||
income tax payables | -1,350 | |||||||||||||||||||||||
*31 march comparatives have been restated to reflect an adjustment to the acquisition-accounting for zs pharma (as detailed in note 25 of the astrazeneca annual report and form 20-f information 2016, page 174) and an adjustment to the acquisition-accounting for acerta pharma (as detailed in note 4 of the full year and fourth quarter 2016 results announcement). |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2021-02-11 | 2020-02-14 | 2019-02-14 | 2018-05-18 | 2017-04-27 | 2017-02-02 |
|---|---|---|---|---|---|---|
cash flows from operating activities | ||||||
profit before tax | 3,916 | 1,548 | 1,993 | 374 | 582 | 2,183 |
finance income and expense | 1,219 | 1,260 | 1,281 | 308 | 322 | 339 |
share of after tax losses of associates and joint ventures | ||||||
depreciation, amortisation and impairment | 3,149 | 3,762 | 3,753 | 709 | 658 | 590 |
movement in working capital and short-term provisions | ||||||
gains on disposal of intangible assets | -1,030 | -1,243 | -1,885 | -65 | ||
fair value movements on contingent consideration arising from business combinations | -272 | -614 | -495 | |||
non-cash and other movements | -276 | 378 | -290 | -242 | -349 | 53 |
cash generated from operations | 7,094 | 4,861 | 3,831 | 105 | 339 | 2,115 |
interest paid | -733 | -774 | -676 | -128 | -189 | -188 |
tax paid | -1,562 | -1,118 | -537 | -117 | -62 | 33 |
net cash inflow from operating activities | 4,799 | 2,969 | 2,618 | 88 | 1,960 | |
cash flows from investing activities | ||||||
acquisition of subsidiaries, net of cash acquired | ||||||
payment of contingent consideration from business combinations | -822 | -709 | -349 | -62 | ||
purchase of property, plant and equipment | -961 | -979 | -1,043 | -213 | -286 | -534 |
disposal of property, plant and equipment | 106 | 37 | 12 | 2 | 9 | 35 |
purchase of intangible assets | -1,645 | -1,481 | -328 | -121 | -99 | -107 |
disposal of intangible assets | 951 | 2,076 | 2,338 | 362 | 51 | 1,310 |
purchase of non-current asset investments | -119 | -13 | -102 | -18 | -20 | |
disposal of non-current asset investments | 1,381 | 18 | 24 | 1 | 8 | |
movement in short-term investments, fixed deposits and other investing instruments | 745 | 194 | ||||
payments to associates and joint ventures | -74 | |||||
disposal of investments in associates and joint ventures | ||||||
interest received | 47 | 124 | 193 | 33 | 45 | 35 |
net cash outflow from investing activities | -285 | -146 | 603 | |||
net cash inflow before financing activities | 4,514 | 2,312 | 3,581 | |||
cash flows from financing activities | ||||||
proceeds from issue of share capital | 30 | 3,525 | 34 | 14 | 17 | 7 |
own shares purchased by employee benefit trust | ||||||
payments to acquire non-controlling interests | ||||||
issue of loans and borrowings | ||||||
repayment of loans and borrowings | ||||||
dividends paid | -3,572 | -3,592 | -3,484 | -2,363 | -2,368 | 0 |
hedge contracts relating to dividend payments | -101 | 4 | -67 | -47 | -32 | 0 |
repayment of obligations under leases | -207 | -186 | ||||
movement in short-term borrowings | 288 | -516 | -98 | 1,733 | 352 | -315 |
payment of acerta pharma share purchase liability | ||||||
net cash outflow from financing activities | -2,203 | -1,765 | -2,044 | -663 | -2,042 | |
net increase in cash and cash equivalents in the period | 2,311 | 547 | 1,537 | |||
cash and cash equivalents at the beginning of the period | 5,223 | 4,671 | 3,172 | 3,172 | 4,924 | 0 |
exchange rate effects | 12 | 5 | -38 | 13 | 14 | -22 |
cash and cash equivalents at the end of the period | 7,546 | 5,223 | 4,671 | 2,655 | 2,838 | 2,237 |
cash and cash equivalents consist of: | ||||||
cash and cash equivalents | 7,832 | 5,369 | 4,831 | 3,005 | 3,129 | 1,928 |
overdrafts | -286 | -146 | -160 | -350 | -291 | 309 |
| ||||||
net cash (outflow)/inflow from financing activities | ||||||
payments upon vesting of employee share awards attributable to business combinations | ||||||
movement in profit-participation liability | 40 | |||||
net cash inflow/(outflow) from financing activities | ||||||
share of after-tax losses of associates and joint ventures | 27 | 116 | ||||
decrease in working capital and short-term provisions | 361 | -887 | ||||
issue of loans | 2,968 | 500 | 2,971 | |||
repayment of loans | -1,609 | -1,500 | -1,400 | |||
reported operating profit | ||||||
increase in working capital and short-term provisions | -346 | -639 | -993 | |||
taxation paid | ||||||
net cash inflow/(outflow) from operating activities | ||||||
net cash inflow/(outflow) before financing activities | 133 | |||||
other investments | ||||||
cash and investments | ||||||
overdrafts and short-term borrowings | ||||||
lease liabilities | ||||||
current instalments of loans | ||||||
loans due after one year | ||||||
interest-bearing loans and borrowings | ||||||
net derivatives | ||||||
net debt | ||||||
for the year ended 31 december | ||||||
movement in profit-participation liability[80] | 150 | |||||
net cash (outflow)/inflow from investing activities | -657 | |||||
leases[29] | ||||||
for the half year ended 30 june | ||||||
movement in short-term investments and fixed deposits | 405 | 436 | 357 | -1 | ||
payments to joint ventures | -187 | -161 | -22 | |||
net cash (outflow)/inflow before financing activities | ||||||
net cash outflow from operating activities | ||||||
leases[28] | ||||||
share of after tax losses in associates and joint ventures | 113 | 14 | 13 | 11 | ||
non-contingent payments on business combinations | ||||||
net cash inflow/(outflow) from investing activities | 963 | 273 | ||||
repayment of obligations under finance leases | -14 | -4 | ||||
net cash (outflow)/inflow from operating activities | -140 | |||||
net decrease in cash and cash equivalents in the period | -530 | -2,100 | 2,259 | |||
cash and cash equivalents consists of: | ||||||
net cash outflows from financing activities | ||||||
finance leases | ||||||
payments made by subsidiaries to non-controlling interests | 0 | |||||
(increase)/decrease in working capital and short-term provisions | ||||||
(gains)/losses on disposal of intangible assets | ||||||
fair value movement on contingent consideration arising from business combinations | ||||||
cash, short-term investments and derivatives | ||||||
upfront payments on business acquisitions | ||||||
net cash outflow before financing activities | -58 | |||||
upfront payments on business combinations | ||||||
payment of contingent consideration on business combinations | -213 | |||||
new long term loans | 3 | |||||
gain on disposal of intangible assets | ||||||
new long-term loans | 8 | |||||
payment of contingent consideration on business acquisitions | ||||||
decrease/(increase) in working capital and short-term provisions |